Amyloid imaging
Author:
- 24 September 2013
- journal article
- Published by Wolters Kluwer Health in Neurology
- Vol. 81 (13) , 1108-1109
Abstract
Human amyloid imaging is one of the great recent translational medicine stories. Beginning with the recognition that Thioflavin T derivatives could be used as PET tracers, through development of Pittsburgh compound B, to Food and Drug Administration (FDA) approval of Florbetapir in 2012, human amyloid imaging has held great promise to allow in vivo inclusive diagnosis of Alzheimer disease (AD), even though the first principle of amyloid PET is that it functions as a surrogate for β-amyloid pathology, and not necessarily as a surrogate for the diagnosis of AD.(1,2.)Keywords
This publication has 8 references indexed in Scilit:
- Using AD biomarker research results for clinical careNeurology, 2013
- Prediction of dementia in MCI patients based on core diagnostic markers for Alzheimer diseaseNeurology, 2013
- Brain Imaging in Alzheimer DiseaseCold Spring Harbor Perspectives in Medicine, 2012
- Biomarkers in translational research of Alzheimer’s DiseaseNeuropharmacology, 2010
- Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of agingNeurobiology of Aging, 2010
- Disclosure ofAPOEGenotype for Risk of Alzheimer's DiseaseNew England Journal of Medicine, 2009
- 11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairmentBrain, 2008
- Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐BAnnals of Neurology, 2004